Replies to post #619709 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Doc,

Assume that NWBO licensed its flaskworks to a CDMO company to get it ready for scale-up production which will be put into operation after DCVax-L gets the approval. Will event of this nature be required to be put in the 10Q?

[hyperopia]

Doc, from the Journal of Translational Medicine:

Patients in both arms continued to receive monthly adjuvant temozolomide (150–200 mg/m2/day?×?5 days every 28 days), interspersed with the DC vaccine or placebo treatments administered on Days 0, 10 and 20, then Months 2, 4 and 8, and thereafter at 6-month intervals starting at month 12. Each DCVax-L treatment involved a dose of 2.5 million autologous tumor lysate-pulsed DCs administered intradermally in the upper arm, alternating arms between injection visits. . .

In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at?
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

BTW - “Patents point to an above 90% purity process developed” doesn’t sound right to me. I don’t think I’ve ever seen you post one, but do you have a link?